お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
1005134

1型糖尿病治療薬の世界市場:形態(インスリン療法、経口薬)別、エンドユーザー(薬局、病院)別の予測(2026年まで)- COVID-19の累積的影響

Type 1 Diabetes Drug Market Research Report by Form, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 188 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.74円
1型糖尿病治療薬の世界市場:形態(インスリン療法、経口薬)別、エンドユーザー(薬局、病院)別の予測(2026年まで)- COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 188 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の1型糖尿病治療薬の市場規模は、2020年の136億6,800万米ドルから、2025年末までに201億981万米ドルに拡大すると予想されています。

COVID-19は、ほぼすべての業界に影響を与えた未曾有の世界の公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されています。当レポートでは、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げ消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19の影響について考察しています。

当レポートは、世界の1型糖尿病治療薬市場について調査しており、市場の機会や課題、成長および抑制要因、COVID-19の累積的影響、形態・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査期間
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査設計
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画を作成する
    • 実行:調査を実施する
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査の成果

第3章 エグゼクティブサマリー

  • 市場展望
  • 形態別市場の展望
  • エンドユーザー別市場の展望
  • 地域別市場の展望
  • 競合他社の見通し

第4章 市場概要

  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 成長要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターのファイブフォース分析

第6章 形態別市場

  • インスリン療法
    • 長時間作用型インスリン
    • 混合型インスリンアナログ製剤
    • 速効型インスリン
  • 経口薬
    • ビグアニド
    • ナトリウムグルコース共輸送体2(SGLT2)阻害剤

第7章 エンドユーザー市場

  • 薬局
  • 病院

第8章 南北アメリカ市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第10章 欧州、中東・アフリカ市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併・買収
    • 契約、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 評価、認知、拡大

第12章 企業プロファイル

  • Albireo
  • Astellas Pharma Inc.
  • Astrazeneca PLC
  • B.braun Melsungen AG
  • Biocon Limited
  • Bristol Myers Squibb
  • C.H. Boehringer Sohn AG & Ko. KG
  • DiaVacs, Inc.
  • Diavacs, Inc.
  • Eli Lilly and Company
  • Glaxosmithkline PLC
  • Janssen Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Macrogenics, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/s
  • Pfizer Inc.
  • Piramal Healthcare Limited
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corp.

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2020 VS 2026 (USD BILLION)
  • FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 (USD BILLION)
  • FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 (USD BILLION)
  • FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
  • FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET: MARKET DYNAMICS
  • FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 VS 2026 (%)
  • FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 VS 2026 (USD BILLION)
  • FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2026
  • FIGURE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2026 (USD BILLION)
  • FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, 2018-2026 (USD BILLION)
  • FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, 2018-2026 (USD BILLION)
  • FIGURE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, 2018-2026 (USD BILLION)
  • FIGURE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2026 (USD BILLION)
  • FIGURE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2026 (USD BILLION)
  • FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, 2018-2026 (USD BILLION)
  • FIGURE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, 2018-2026 (USD BILLION)
  • FIGURE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2026 (USD BILLION)
  • FIGURE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, 2018-2026 (USD BILLION)
  • FIGURE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, 2018-2026 (USD BILLION)
  • FIGURE 31. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, 2018-2026 (USD BILLION)
  • FIGURE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 34. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, 2018-2026 (USD BILLION)
  • FIGURE 35. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 36. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 VS 2026 (%)
  • FIGURE 37. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 VS 2026 (USD BILLION)
  • FIGURE 38. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2026
  • FIGURE 39. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, 2018-2026 (USD BILLION)
  • FIGURE 40. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 41. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, 2018-2026 (USD BILLION)
  • FIGURE 42. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 43. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 44. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 45. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 46. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 47. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 48. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 49. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 50. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 51. CALIFORNIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 52. FLORIDA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 53. ILLINOIS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 54. NEW YORK TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 55. OHIO TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 56. PENNSYLVANIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 57. TEXAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 58. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 59. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 60. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 61. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 62. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 63. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 64. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 65. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 66. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 67. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 68. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 69. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 70. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 71. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 72. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 73. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 74. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 75. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 76. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 77. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 78. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 79. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 80. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 81. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 82. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 83. GLOBAL TYPE 1 DIABETES DRUG MARKET: FPNV POSITIONING MATRIX
  • FIGURE 84. GLOBAL TYPE 1 DIABETES DRUG MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 85. GLOBAL TYPE 1 DIABETES DRUG MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 86. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL TYPE 1 DIABETES DRUG MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 20. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 21. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 22. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 23. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 24. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 25. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 26. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 27. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 28. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 29. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 30. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 31. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 32. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 33. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 34. CALIFORNIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 35. CALIFORNIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 36. FLORIDA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 37. FLORIDA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 38. ILLINOIS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 39. ILLINOIS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 40. NEW YORK TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 41. NEW YORK TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 42. OHIO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 43. OHIO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 44. PENNSYLVANIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 45. PENNSYLVANIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 46. TEXAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 47. TEXAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 48. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 49. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 50. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 51. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 52. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 53. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 54. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 55. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 56. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 57. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 58. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 59. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 60. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 61. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 62. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 63. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 64. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 65. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 66. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 70. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 71. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 72. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 73. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 74. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 75. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 76. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 77. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 78. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 79. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 80. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 81. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 82. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 83. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 84. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 85. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 86. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 87. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 88. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 89. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 90. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 91. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 92. GLOBAL TYPE 1 DIABETES DRUG MARKET: SCORES
  • TABLE 93. GLOBAL TYPE 1 DIABETES DRUG MARKET: BUSINESS STRATEGY
  • TABLE 94. GLOBAL TYPE 1 DIABETES DRUG MARKET: PRODUCT SATISFACTION
  • TABLE 95. GLOBAL TYPE 1 DIABETES DRUG MARKET: RANKING
  • TABLE 96. GLOBAL TYPE 1 DIABETES DRUG MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 97. GLOBAL TYPE 1 DIABETES DRUG MARKET: SHARE, BY COMPANY, 2020
  • TABLE 98. GLOBAL TYPE 1 DIABETES DRUG MARKET: MERGER & ACQUISITION
  • TABLE 99. GLOBAL TYPE 1 DIABETES DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 100. GLOBAL TYPE 1 DIABETES DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 101. GLOBAL TYPE 1 DIABETES DRUG MARKET: INVESTMENT & FUNDING
  • TABLE 102. GLOBAL TYPE 1 DIABETES DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 103. GLOBAL TYPE 1 DIABETES DRUG MARKET: LICENSE & PRICING
  • TABLE 104. GLOBAL TYPE 1 DIABETES DRUG MARKET: CONTACT DETAILS
目次
Product Code: MRR-43676CF429F6

The Global Type 1 Diabetes Drug Market size was estimated at USD 13.66 Billion in 2020 and expected to reach USD 14.83 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 8.86% to reach USD 22.75 Billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Type 1 Diabetes Drug to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Form, the Type 1 Diabetes Drug Market was studied across Insulin Therapy and Oral Medication. The Insulin Therapy is further studied across Long-Acting Insulin, Premix Analogs, and Rapid Acting Insulin. The Oral Medication is further studied across Biguanides and Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.

Based on End User, the Type 1 Diabetes Drug Market was studied across Drugstore and Hospital.

Based on Geography, the Type 1 Diabetes Drug Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Type 1 Diabetes Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Type 1 Diabetes Drug Market, including Albireo, Astellas Pharma Inc., Astrazeneca PLC, B.braun Melsungen AG, Biocon Limited, Bristol Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, DiaVacs, Inc., Diavacs, Inc., Eli Lilly and Company, Glaxosmithkline PLC, Janssen Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin Limited, Macrogenics, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Novo Nordisk A/s, Pfizer Inc., Piramal Healthcare Limited, Samsung Bioepis Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XOMA Corp..

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Type 1 Diabetes Drug Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 1 Diabetes Drug Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 1 Diabetes Drug Market?
  • 4. What is the competitive strategic window for opportunities in the Global Type 1 Diabetes Drug Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Type 1 Diabetes Drug Market?
  • 6. What is the market share of the leading vendors in the Global Type 1 Diabetes Drug Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Type 1 Diabetes Drug Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Form Outlook
  • 3.4. End User Outlook
  • 3.5. Geography Outlook
  • 3.6. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of type 1 diabetes globally
      • 5.1.1.2. Increasing healthcare expenditure with rising disposable income
      • 5.1.1.3. Rising patient awareness on type 1 diabetes treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiration of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging introduction of novel drugs to treat diabetes
      • 5.1.3.2. Surge in research and development activities for type 1 anti-diabetic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Strict regulations for the approval drugs
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Type 1 Diabetes Drug Market, by Form

  • 6.1. Introduction
  • 6.2. Insulin Therapy
    • 6.2.1. Long-Acting Insulin
    • 6.2.2. Premix Analogs
    • 6.2.3. Rapid Acting Insulin
  • 6.3. Oral Medication
    • 6.3.1. Biguanides
      • 6.3.1.1. Metformine
      • 6.3.1.2. Metformine Extended-Release
    • 6.3.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
      • 6.3.2.1. Canaglifozine
      • 6.3.2.2. Dapagliflozine
      • 6.3.2.3. Empagliflozine
      • 6.3.2.4. Ertugliflozine

7. Type 1 Diabetes Drug Market, by End User

  • 7.1. Introduction
  • 7.2. Drugstore
  • 7.3. Hospital

8. Americas Type 1 Diabetes Drug Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States
    • 8.6.1. California
    • 8.6.2. Florida
    • 8.6.3. Illinois
    • 8.6.4. New York
    • 8.6.5. Ohio
    • 8.6.6. Pennsylvania
    • 8.6.7. Texas

9. Asia-Pacific Type 1 Diabetes Drug Market

  • 9.1. Introduction
  • 9.2. China
  • 9.3. India
  • 9.4. Indonesia
  • 9.5. Japan
  • 9.6. Malaysia
  • 9.7. Philippines
  • 9.8. South Korea
  • 9.9. Thailand

10. Europe, Middle East & Africa Type 1 Diabetes Drug Market

  • 10.1. Introduction
  • 10.2. France
  • 10.3. Germany
  • 10.4. Italy
  • 10.5. Netherlands
  • 10.6. Qatar
  • 10.7. Russia
  • 10.8. Saudi Arabia
  • 10.9. South Africa
  • 10.10. Spain
  • 10.11. United Arab Emirates
  • 10.12. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
    • 11.1.1. Quadrants
    • 11.1.2. Business Strategy
    • 11.1.3. Product Satisfaction
  • 11.2. Market Ranking Analysis
  • 11.3. Market Share Analysis, By Quadrant
  • 11.4. Market Share Analysis, By Company
  • 11.5. Competitive Scenario
    • 11.5.1. Merger & Acquisition
    • 11.5.2. Agreement, Collaboration, & Partnership
    • 11.5.3. New Product Launch & Enhancement
    • 11.5.4. Investment & Funding
    • 11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

  • 12.1. Albireo
  • 12.2. Astellas Pharma Inc.
  • 12.3. Astrazeneca PLC
  • 12.4. B.braun Melsungen AG
  • 12.5. Biocon Limited
  • 12.6. Bristol Myers Squibb
  • 12.7. C.H. Boehringer Sohn AG & Ko. KG
  • 12.8. DiaVacs, Inc.
  • 12.9. Diavacs, Inc.
  • 12.10. Eli Lilly and Company
  • 12.11. Glaxosmithkline PLC
  • 12.12. Janssen Pharmaceuticals
  • 12.13. Johnson & Johnson Services, Inc.
  • 12.14. Lupin Limited
  • 12.15. Macrogenics, Inc.
  • 12.16. Merck & Co., Inc.
  • 12.17. Mylan N.V.
  • 12.18. Novartis International AG
  • 12.19. Novo Nordisk A/s
  • 12.20. Pfizer Inc.
  • 12.21. Piramal Healthcare Limited
  • 12.22. Samsung Bioepis Co., Ltd.
  • 12.23. Sanofi S.A.
  • 12.24. Teva Pharmaceutical Industries Ltd.
  • 12.25. XOMA Corp.

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
  • 13.3. Contact Details
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.